- Home
- UCL vs LVTX Comparison
UCL vs LVTX Comparison
Compare UCL & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- LVTX
- Stock Information
- Founded
- UCL 2014
- LVTX 2016
- Country
- UCL Hong Kong
- LVTX Netherlands
- Employees
- UCL N/A
- LVTX N/A
- Industry
- UCL Telecommunications Equipment
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- UCL Consumer Discretionary
- LVTX Health Care
- Exchange
- UCL Nasdaq
- LVTX Nasdaq
- Market Cap
- UCL 70.6M
- LVTX 33.9M
- IPO Year
- UCL 2020
- LVTX 2021
- Fundamental
- Price
- UCL $1.83
- LVTX N/A
- Analyst Decision
- UCL
- LVTX Hold
- Analyst Count
- UCL 0
- LVTX 3
- Target Price
- UCL N/A
- LVTX $1.75
- AVG Volume (30 Days)
- UCL 58.4K
- LVTX 12.3K
- Earning Date
- UCL 08-13-2025
- LVTX 08-19-2025
- Dividend Yield
- UCL N/A
- LVTX N/A
- EPS Growth
- UCL N/A
- LVTX N/A
- EPS
- UCL 0.09
- LVTX N/A
- Revenue
- UCL $92,256,000.00
- LVTX $4,990,000.00
- Revenue This Year
- UCL $6.09
- LVTX N/A
- Revenue Next Year
- UCL $7.01
- LVTX N/A
- P/E Ratio
- UCL $19.62
- LVTX N/A
- Revenue Growth
- UCL 7.65
- LVTX N/A
- 52 Week Low
- UCL $0.80
- LVTX $0.85
- 52 Week High
- UCL $3.30
- LVTX $2.39
- Technical
- Relative Strength Index (RSI)
- UCL 54.00
- LVTX 52.45
- Support Level
- UCL $1.79
- LVTX $1.27
- Resistance Level
- UCL $1.99
- LVTX $1.38
- Average True Range (ATR)
- UCL 0.16
- LVTX 0.04
- MACD
- UCL -0.03
- LVTX -0.00
- Stochastic Oscillator
- UCL 19.05
- LVTX 44.64
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.